CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer.
- 1 opens in JClub
CRISPR screens reveal Dusp5 and Zfp219 as key regulators of age-related T cell dysfunction, with Zfp219 ablation improving tumor clearance in aged mice.
- Why it matters: Understanding the drivers of T cell dysfunction in aged tumors is crucial for improving cancer immunotherapy outcomes in older patients, who often respond poorly.
- What they did: Single-cell CRISPR screens targeting aged tumor-infiltrating T cells identified Dusp5 and Zfp219; their manipulation affected T cell proliferation, epigenetic reprogramming, and cytotoxicity.
- The result: Targeting Dusp5 and Zfp219 restored T cell function, enhanced antitumor immunity, and synergized with checkpoint inhibitors, offering potential strategies to rejuvenate immune responses in elderly cancer patients.